-
Je něco špatně v tomto záznamu ?
Bloodstream Stability Predetermines the Antitumor Efficacy of Micellar Polymer-Doxorubicin Drug Conjugates with pH-Triggered Drug Release
P. Chytil, M. Šírová, J. Kudláčová, B. Říhová, K. Ulbrich, T. Etrych,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- doxorubicin chemie farmakokinetika terapeutické užití MeSH
- hydrofobní a hydrofilní interakce MeSH
- koncentrace vodíkových iontů MeSH
- lymfom krev farmakoterapie MeSH
- micely MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- nosiče léků chemie MeSH
- polymery chemie MeSH
- protinádorové látky chemie farmakokinetika terapeutické užití MeSH
- uvolňování léčiv MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Herein, the biodegradable micelle-forming amphiphilic N-(2-hydroxypropyl) methacrylamide (HPMA)-based polymer conjugates with the anticancer drug doxorubicin (Dox) designed for enhanced tumor accumulation were investigated, and the influence of their stability in the bloodstream on biodistribution, namely, tumor uptake, and in vivo antitumor efficacy were evaluated in detail. Dox was attached to the polymer carrier by a hydrazone bond enabling pH-controlled drug release. While the polymer-drug conjugates were stable in a buffer at pH 7.4 (mimicking bloodstream environment), Dox was released in a buffer under mild acidic conditions modeling the tumor microenvironment or cells. The amphiphilic polymer carriers differed in the structure of hydrophobic cholesterol derivative moieties bound to the HPMA copolymers via a hydrolyzable hydrazone bond, exhibiting different rates of micellar structure disintegration at various pH values. Considerable dependence of the studied polymer-drug conjugate biodistribution on the stability of the micellar structure was observed in neutral, bloodstream-mimicking, environment, showing that a faster rate of the micelle disintegration in pH 7.4 increased the conjugate blood clearance, decreased tumor accumulation, and significantly reduced the tumor:blood and tumor:muscle ratios. Similarly, the final therapeutic outcome was strongly affected by the stability of the micellar structure because the most stable micellar conjugate showed an almost similar therapeutic outcome as the water-soluble, nondegradable, high-molecular-weight starlike HPMA copolymer-Dox conjugate, which was highly efficient in the treatment of solid tumors in mice. Based on the results, we conclude that the bloodstream stability of micellar polymer-anticancer drug conjugates, in addition to their low side toxicity, is a crucial parameter for their efficient solid tumor accumulation and high in vivo antitumor activity.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035351
- 003
- CZ-PrNML
- 005
- 20191015105023.0
- 007
- ta
- 008
- 191007s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.molpharmaceut.8b00156 $2 doi
- 035 __
- $a (PubMed)29543465
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Chytil, Petr $u Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstı́ 2 , 162 06 Prague 6 , Czech Republic.
- 245 10
- $a Bloodstream Stability Predetermines the Antitumor Efficacy of Micellar Polymer-Doxorubicin Drug Conjugates with pH-Triggered Drug Release / $c P. Chytil, M. Šírová, J. Kudláčová, B. Říhová, K. Ulbrich, T. Etrych,
- 520 9_
- $a Herein, the biodegradable micelle-forming amphiphilic N-(2-hydroxypropyl) methacrylamide (HPMA)-based polymer conjugates with the anticancer drug doxorubicin (Dox) designed for enhanced tumor accumulation were investigated, and the influence of their stability in the bloodstream on biodistribution, namely, tumor uptake, and in vivo antitumor efficacy were evaluated in detail. Dox was attached to the polymer carrier by a hydrazone bond enabling pH-controlled drug release. While the polymer-drug conjugates were stable in a buffer at pH 7.4 (mimicking bloodstream environment), Dox was released in a buffer under mild acidic conditions modeling the tumor microenvironment or cells. The amphiphilic polymer carriers differed in the structure of hydrophobic cholesterol derivative moieties bound to the HPMA copolymers via a hydrolyzable hydrazone bond, exhibiting different rates of micellar structure disintegration at various pH values. Considerable dependence of the studied polymer-drug conjugate biodistribution on the stability of the micellar structure was observed in neutral, bloodstream-mimicking, environment, showing that a faster rate of the micelle disintegration in pH 7.4 increased the conjugate blood clearance, decreased tumor accumulation, and significantly reduced the tumor:blood and tumor:muscle ratios. Similarly, the final therapeutic outcome was strongly affected by the stability of the micellar structure because the most stable micellar conjugate showed an almost similar therapeutic outcome as the water-soluble, nondegradable, high-molecular-weight starlike HPMA copolymer-Dox conjugate, which was highly efficient in the treatment of solid tumors in mice. Based on the results, we conclude that the bloodstream stability of micellar polymer-anticancer drug conjugates, in addition to their low side toxicity, is a crucial parameter for their efficient solid tumor accumulation and high in vivo antitumor activity.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x chemie $x farmakokinetika $x terapeutické užití $7 D000970
- 650 _2
- $a doxorubicin $x chemie $x farmakokinetika $x terapeutické užití $7 D004317
- 650 _2
- $a nosiče léků $x chemie $7 D004337
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a koncentrace vodíkových iontů $7 D006863
- 650 _2
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 _2
- $a lymfom $x krev $x farmakoterapie $7 D008223
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a micely $7 D008823
- 650 _2
- $a polymery $x chemie $7 D011108
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Šírová, Milada $u Institute of Microbiology, Czech Academy of Sciences , Vídeňská 1083 , 142 20 Prague 4 , Czech Republic.
- 700 1_
- $a Kudláčová, Júlia $u Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstı́ 2 , 162 06 Prague 6 , Czech Republic.
- 700 1_
- $a Říhová, Blanka $u Institute of Microbiology, Czech Academy of Sciences , Vídeňská 1083 , 142 20 Prague 4 , Czech Republic.
- 700 1_
- $a Ulbrich, Karel $u Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstı́ 2 , 162 06 Prague 6 , Czech Republic.
- 700 1_
- $a Etrych, Tomáš $u Institute of Macromolecular Chemistry, Czech Academy of Sciences , Heyrovského náměstı́ 2 , 162 06 Prague 6 , Czech Republic.
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 15, č. 9 (2018), s. 3654-3663
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29543465 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191015105449 $b ABA008
- 999 __
- $a ok $b bmc $g 1452011 $s 1073901
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 15 $c 9 $d 3654-3663 $e 20180321 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- LZP __
- $a Pubmed-20191007